Value investors typically seek-out low valuation multiples but are occasionally ensnared in the dreaded "value-trap". One reason this can occur is that the company's assets cease producing income sooner than anticipated. The article highlights a number of reasons why investors in pharmaceutical stocks should be particularly wary of such risks.
